All bills
H.R. 10369·119th Congress·House Bill

Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026

Stage not supplied

The source supplies the latest action, but no lifecycle stage.

Latest action (14 Sep 2026): Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

What this bill does

H.R. 10369, titled the "Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026," proposes new requirements for pharmacy benefit managers (PBMs) operating within Medicare Part D prescription drug plans. The bill would mandate a standardized public bidding process for PBM services, requiring contracts to solicit bids annually. PBMs would need to disclose detailed financial information, including expected revenues from various sources and projected costs related to prescription drugs.

This legislation primarily affects Medicare Part D prescription drug plans and their contracted pharmacy benefit managers. It aims to increase transparency regarding the net effective cost of prescription drugs by requiring PBMs to provide specific data in their bids. The bill also introduces enhanced oversight measures for Part D plans, including audits and monitoring of cost-sharing and formulary changes to prevent potential "bait-and-switch" practices.

Introduced in the House of Representatives on September 14, 2026, H.R. 10369 has been referred to the Committees on Energy and Commerce, Ways and Means, and Education and Workforce for consideration. The bill's next steps would involve committee review, potential amendments, and votes within those committees. If it passes the committees, it would proceed to the full House for a vote, and subsequently to the Senate if passed by the House.

Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.

Timeline

  1. 14 Sep 2026

    Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Common questions

What does H.R. 10369 do?
H.R. 10369, titled the "Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026," proposes new requirements for pharmacy benefit managers (PBMs) operating within Medicare Part D prescription drug plans. The bill would mandate a standardized public bidding process for PBM services, requiring contracts to solicit bids annually. PBMs would need to disclose detailed financial information, including expected revenues from various sources and projected costs related to prescription drugs. This legislation primarily affects Medicare Part D prescription drug plans and their contracted pharmacy benefit managers. It aims to increase transparency regarding the net effective cost of prescription drugs by requiring PBMs to provide specific data in their bids. The bill also introduces enhanced oversight measures for Part D plans, including audits and monitoring of cost-sharing and formulary changes to prevent potential "bait-and-switch" practices. Introduced in the House of Representatives on September 14, 2026, H.R. 10369 has been referred to the Committees on Energy and Commerce, Ways and Means, and Education and Workforce for consideration. The bill's next steps would involve committee review, potential amendments, and votes within those committees. If it passes the committees, it would proceed to the full House for a vote, and subsequently to the Senate if passed by the House.
Has H.R. 10369 become law?
The source does not supply a confirmed lifecycle stage for H.R. 10369. Check the latest action and official source below.
Who sponsored H.R. 10369?
H.R. 10369 was sponsored by Rep. Mackenzie, Ryan [R-PA-7] (R-PA), with 4 cosponsors.
What's the latest action on H.R. 10369?
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (14 Sep 2026).

Related bills in Health

More bills from Rep. Mackenzie, Ryan [R-PA-7]

Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.